OCA at 07:20, 12 July 2023

OCA — Wed, 12 Jul 2023 07:20:36 GMT

←Older revision		Revision as of 07:20, 12 July 2023
Line 1:		Line 1:
-	'''Unreleased structure'''

-	The entry ~~8fc7~~ is ~~ON HOLD~~	+	==Cryo-EM structure of the human TRPV4 - RhoA in complex with GSK2798745==
		+	<StructureSection load='8fc7' size='340' side='right'caption='[[8fc7]], [[Resolution\|resolution]] 3.30Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[8fc7]] is a 8 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8FC7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8FC7 FirstGlance]. <br>
		+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution\|Resolution]] 3.3Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GDP:GUANOSINE-5-DIPHOSPHATE'>GDP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=XPW:1-({(5S,7S)-3-[5-(2-hydroxypropan-2-yl)pyrazin-2-yl]-7-methyl-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl}methyl)-1H-benzimidazole-6-carbonitrile'>XPW</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8fc7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8fc7 OCA], [https://pdbe.org/8fc7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8fc7 RCSB], [https://www.ebi.ac.uk/pdbsum/8fc7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8fc7 ProSAT]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[https://www.uniprot.org/uniprot/TRPV4_HUMAN TRPV4_HUMAN] Spondylometaphyseal dysplasia, Kozlowski type;Familial digital arthropathy-brachydactyly;Autosomal dominant brachyolmia;Autosomal dominant congenital benign spinal muscular atrophy;Parastremmatic dwarfism;Spondyloepiphyseal dysplasia, Maroteaux type;Autosomal dominant Charcot-Marie-Tooth disease type 2C;Metatropic dysplasia. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry. The disease is caused by mutations affecting the gene represented in this entry.
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/TRPV4_HUMAN TRPV4_HUMAN] Non-selective calcium permeant cation channel probably involved in osmotic sensitivity and mechanosensitivity. Activation by exposure to hypotonicity within the physiological range exhibits an outward rectification. Also activated by low pH, citrate and phorbol esters. Increase of intracellular Ca(2+) potentiates currents. Channel activity seems to be regulated by a calmodulin-dependent mechanism with a negative feedback mechanism. Promotes cell-cell junction formation in skin keratinocytes and plays an important role in the formation and/or maintenance of functional intercellular barriers. Acts as a regulator of intracellular Ca(2+) in synoviocytes. Plays an obligatory role as a molecular component in the nonselective cation channel activation induced by 4-alpha-phorbol 12,13-didecanoate and hypotonic stimulation in synoviocytes and also regulates production of IL-8.<ref>PMID:11025659</ref> <ref>PMID:12724311</ref> <ref>PMID:19759329</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Crosstalk between ion channels and small GTPases is critical during homeostasis and disease, but little is known about the structural underpinnings of these interactions. TRPV4 is a polymodal, calcium-permeable cation channel that has emerged as a potential therapeutic target in multiple conditions. Gain-of-function mutations also cause hereditary neuromuscular disease. Here, we present cryo-EM structures of human TRPV4 in complex with RhoA in the ligand-free, antagonist-bound closed, and agonist-bound open states. These structures reveal the mechanism of ligand-dependent TRPV4 gating. Channel activation is associated with rigid-body rotation of the intracellular ankyrin repeat domain, but state-dependent interaction with membrane-anchored RhoA constrains this movement. Notably, many residues at the TRPV4-RhoA interface are mutated in disease and perturbing this interface by introducing mutations into either TRPV4 or RhoA increases TRPV4 channel activity. Together, these results suggest that RhoA serves as an auxiliary subunit for TRPV4, regulating TRPV4-mediated calcium homeostasis and disruption of TRPV4-RhoA interactions can lead to TRPV4-related neuromuscular disease. These insights will help facilitate TRPV4 therapeutics development.

-	~~Authors~~:	+	TRPV4-Rho GTPase complex structures reveal mechanisms of gating and disease.,Kwon DH, Zhang F, McCray BA, Feng S, Kumar M, Sullivan JM, Im W, Sumner CJ, Lee SY Nat Commun. 2023 Jun 23;14(1):3732. doi: 10.1038/s41467-023-39345-0. PMID:37353484<ref>PMID:37353484</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased~~ Structures]]	+	</div>
		+	<div class="pdbe-citations 8fc7" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Homo sapiens]]
		+	[[Category: Large Structures]]
		+	[[Category: Kwon DH]]
		+	[[Category: Lee S-Y]]
		+	[[Category: Zhang F]]

OCA at 07:47, 19 April 2023

OCA — Wed, 19 Apr 2023 07:47:18 GMT

←Older revision		Revision as of 07:47, 19 April 2023
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 8fc7 is ON HOLD ~~until Paper Publication~~	+	The entry 8fc7 is ON HOLD

	Authors:		Authors:

OCA at 05:07, 8 February 2023

OCA — Wed, 08 Feb 2023 05:07:52 GMT

←Older revision		Revision as of 05:07, 8 February 2023
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 8fc7 is ON HOLD	+	The entry 8fc7 is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "8fc7" [edit=sysop:move=sysop]

OCA — Wed, 07 Dec 2022 05:42:52 GMT

Protected "8fc7" [edit=sysop:move=sysop]

←Older revision

Revision as of 05:42, 7 December 2022

OCA: New page: '''Unreleased structure''' The entry 8fc7 is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 07 Dec 2022 05:42:50 GMT

New page: '''Unreleased structure''' The entry 8fc7 is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 8fc7 is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]

8fc7 - Revision history

OCA at 07:20, 12 July 2023

OCA at 07:47, 19 April 2023

OCA at 05:07, 8 February 2023

OCA: Protected "8fc7" [edit=sysop:move=sysop]

OCA: New page: '''Unreleased structure''' The entry 8fc7 is ON HOLD Authors: Description: Category: Unreleased Structures